EODData

MEMBERSHIP REGISTER LOG IN

AMEX, KAPA: Kairos Pharma Ltd

16 Oct 2025
LAST:

1.170

CHANGE:
 0.08		OPEN:
1.250		HIGH:
1.280		ASK:
0.000		VOLUME:
337.1K
CHG(%):
6.40		PREV:
1.250		LOW:
1.160		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
16 Oct 251.2501.2801.1601.170337.1K
16 Oct 251.2601.2801.1501.170324K
15 Oct 251.3101.3101.2201.250395.3K
15 Oct 251.3101.3101.2201.250395.4K
14 Oct 251.2201.3101.2101.290400.4K
14 Oct 251.2201.3101.1901.290390.5K
13 Oct 251.2701.2801.1601.210190.1K
13 Oct 251.2001.2701.2001.210197.5K
10 Oct 251.3201.3201.1601.160643.6K
09 Oct 251.3401.3701.2301.320529.4K

COMPANY PROFILE

Name:Kairos Pharma Ltd
About:Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Sector:Healthcare
Industry:Biotechnology
Address:2355 Westwood Boulevard, Los Angeles, CA, United States, 90064
Website:https://kairospharma.com
CIK:0001962011
ISIN:US48301N1046
FIGI:BBG01JLR1R85

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.223.9%
MA10:1.246.2%
MA20:1.202.4%
MA50:1.3011.1%
MA100:1.0215.0%
MA200:1.0510.9%
STO9:4.76 
STO14:20.00 
RSI14:54.32
WPR14:-75.00
MTM14:0.05
ROC14:0.04 
ATR:0.11 
Week High:1.3717.1%
Week Low:1.160.9%
Month High:1.8558.1%
Month Low:1.0610.9%
Year High:3.25177.8%
Year Low:0.40192.5%
Volatility:97.69